1 recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Recruiting 1 |
Follow Dominik Paul Modest: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer Panitumumab 20 milligram/ML, Bevacizumab, Trifluridine/Tipiracil Hydrochloride - Metastatic Colorectal Cancer | Phase 2 | Recruiting | Dominik Paul Modest | 153 | 2021-12-17 | 2024-02-15 |
Bevacizumab (1) · Trifluridine (1) · trifluridine tipiracil drug combination (1)
Germany (1)
2019 (1)